{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:56Z","timestamp":1787009456280,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced pancreatic ductal adenocarcinoma (aPDAC) has a poor prognosis with median overall survival (OS) of about 12 months. It is therefore important to explore factors that predict the efficacy of third-line chemotherapy (L3) to identify patients who may benefit from this controversial treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective cohort-based study of 202 French patients treated for aPDAC who received at least three treatment lines from January 2011 to March 2022. We used penalized Cox regressions to predict progression-free survival (PFS) and OS in patients on L3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age at the start of L3 was 64.3 years old and 63.5% had an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of 0 or 1. The most frequent regimens for L3 were FOLFIRI (25.2% of patients). Median PFS was 2.2 months, while median OS was 4.2 months. In multivariate models, we identified the following predictors of both PFS and OS: age, sex, surgery for the primary tumor, FOLFIRINOX as the first-line therapy, duration of first and second-line treatments, and for L3: ECOG-PS level, peritoneum, liver and\/or lung metastasis and depletion of therapeutic resources. The model incorporating these factors provided acceptable discrimination between event and event-free patients at 6 months post-L3 (area under the ROC curve of 0.83 for PFS and 0.73 for OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The characteristics of patients and their aPDAC are readily available in clinical practice and were able to predict survival with L3. The online calculator we propose here could help physicians determine whether L3 chemotherapy would be beneficial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf125","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T08:14:58Z","timestamp":1745655298000},"source":"Crossref","is-referenced-by-count":2,"title":["Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3147-1350","authenticated-orcid":false,"given":"Camille","family":"Evrard","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Poitiers University Hospital , Poitiers 86000 ,","place":["France"]},{"name":"ProDicET, UR 24144, University of Poitiers , 86000 Poitiers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pelras","sequence":"additional","affiliation":[{"name":"Direction of research and Innovation, Platform for Methodology and Biostatistics, Poitiers University Hospital , Poitiers 86000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rivet","sequence":"additional","affiliation":[{"name":"Hepato-Gastroenterology Department, Poitiers University Hospital , Poitiers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4337-286X","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Bachet","sequence":"additional","affiliation":[{"name":"Sorbonne University, Department of Hepato-Gastroenterology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dubreuil","sequence":"additional","affiliation":[{"name":"Sorbonne University, Department of Hepato-Gastroenterology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Pointet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, H\u00f4pital Europ\u00e9en Georges-Pompidou, AP-HP, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, H\u00f4pital Europ\u00e9en Georges-Pompidou, AP-HP, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Widad","family":"Lahlou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, H\u00f4pital Europ\u00e9en Georges-Pompidou, AP-HP, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Portal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, H\u00f4pital Europ\u00e9en Georges-Pompidou, AP-HP, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Lep\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, H\u00f4pital Europ\u00e9en Georges-Pompidou, AP-HP, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, Tours University Hospital , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Chautard","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, Tours University Hospital , Tours ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Williet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU Saint-\u00c9tienne , Saint-Etienne, Rh\u00f4ne-Alpes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Phelip","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHU Saint-\u00c9tienne , Saint-Etienne, Rh\u00f4ne-Alpes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9lia","family":"Coutzac","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Leon Berard Center , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Soularue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kremlin Bic\u00eatre Hospital, Assistance publique-H\u00f4pitaux de Paris (AP-HP), Paris Sud University , Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lysiane","family":"Marthey","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kremlin Bic\u00eatre Hospital, Assistance publique-H\u00f4pitaux de Paris (AP-HP), Paris Sud University , Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00ebf","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kremlin Bic\u00eatre Hospital, Assistance publique-H\u00f4pitaux de Paris (AP-HP), Paris Sud University , Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thirot Bidault","sequence":"additional","affiliation":[{"name":"Oncology Institute Paris Sud, Hopital Priv\u00e9 d\u2019Antony ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Artru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Digestive Oncology Jean Mermoz Hospital , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Desrame","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Digestive Oncology Jean Mermoz Hospital , Lyon ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Le Roy","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery and Oncology, Clermont-Ferrand University Hospital ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Jary","sequence":"additional","affiliation":[{"name":"Department of Digestive Surgery and Oncology, Clermont-Ferrand University Hospital ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Hammel","sequence":"additional","affiliation":[{"name":"Digestive and Medical Oncology Department, H\u00f4pital Paul Brousse and University Paris-Saclay , Villejuif ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Trouilloud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint-Antoine Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Lourenco","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Saint-Louis Teaching Hospital , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Amiens-Picardie University Hospital , Amiens ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5267-6190","authenticated-orcid":false,"given":"La\u00ebtitia","family":"Dahan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital La Timone, Aix-Marseille University , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-585X","authenticated-orcid":false,"given":"Simon","family":"Pernot","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Bergoni\u00e9 , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"B\u00e9chade","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institut Bergoni\u00e9 , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Pozet","sequence":"additional","affiliation":[{"name":"Methodology and Quality of Life in Oncology Unit, (Inserm UMR 1098), Besan\u00e7on University Hospital , Besan\u00e7on ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[{"name":"Methodology and Quality of Life in Oncology Unit, (Inserm UMR 1098), Besan\u00e7on University Hospital , Besan\u00e7on ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Locher","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Meaux Hospital , Meaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Dr\u00e9anic","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy Unit, Cochin Hospital, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), Paris Descartes University , Sorbonne Paris Cit\u00e9, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Coriat","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, H\u00f4pital Cochin , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9linda","family":"Tchoundjeu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Digestive Oncology, Orleans Regional Hospital (CHRO) , Orleans ,","place":["France CI"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Foucher","sequence":"additional","affiliation":[{"name":"Direction of research and Innovation, Platform for Methodology and Biostatistics, Poitiers University Hospital , Poitiers 86000 ,","place":["France"]},{"name":"CI,C 1402, Inserm, Poitiers University, Poitiers University Hospital , Poitiers 86000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[{"name":"ProDicET, UR 24144, University of Poitiers , 86000 Poitiers ,","place":["France"]},{"name":"Hepato-Gastroenterology Department, Poitiers University Hospital , Poitiers ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"key":"2025061401595509200_CIT0001","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/PPO.0000000000000286","article-title":"Advances in the genetics and biology of pancreatic cancer","volume":"23","author":"Aguirre","year":"2017","journal-title":"Cancer J"},{"key":"2025061401595509200_CIT0002","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.dld.2018.08.008","article-title":"Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)","volume":"50","author":"Neuzillet","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2025061401595509200_CIT0003","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","article-title":"Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a surveillance epidemiology and end results database analysis","volume":"23","author":"Oweira","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"11","key":"2025061401595509200_CIT0004","doi-asserted-by":"crossref","first-page":"3711039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"key":"2025061401595509200_CIT0005","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX vs gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2025061401595509200_CIT0006","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2025061401595509200_CIT0007","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"2","key":"2025061401595509200_CIT0008","first-page":"130","article-title":"Gemcitabine treatment in pancreatic cancer \u2013 prognostic factors and outcome","volume":"20","author":"Andersson","year":"2007","journal-title":"Ann Gastroenterol"},{"key":"2025061401595509200_CIT0009","first-page":"102","article-title":"Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter","volume":"17","author":"Inal","year":"2012","journal-title":"Offi J Balkan Union Oncol"},{"key":"2025061401595509200_CIT0010","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cncr.27734","article-title":"Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy","volume":"119","author":"Bauer","year":"2013","journal-title":"Cancer"},{"key":"2025061401595509200_CIT0011","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1136\/gut.2010.216135","article-title":"Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)","volume":"59","author":"Dahan","year":"2010","journal-title":"Gut"},{"key":"2025061401595509200_CIT0012","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","article-title":"Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III Trial","volume":"23","author":"Louvet","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025061401595509200_CIT0013","doi-asserted-by":"publisher","first-page":"e000587","DOI":"10.1136\/esmoopen-2019-000587","article-title":"First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study","volume":"5","author":"Taieb","year":"2020","journal-title":"ESMO Open"},{"key":"2025061401595509200_CIT0014","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1)","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"2025061401595509200_CIT0015","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin, folinic acid, and fluorouracil vs folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025061401595509200_CIT0016","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: A Randomized Phase III Study of Fluorouracil\/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025061401595509200_CIT0017","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025061401595509200_CIT0018","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4143\/crt.2019.190","article-title":"Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma","volume":"52","author":"Lee","year":"2020","journal-title":"Cancer Res Treat"},{"key":"2025061401595509200_CIT0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06945-8","article-title":"Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer","volume":"20","author":"Sawada","year":"2020","journal-title":"BMC Cancer"},{"key":"2025061401595509200_CIT0020","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.23.00795","article-title":"Gemcitabine and paclitaxel vs gemcitabine alone after 5-fluorouracil, oxaliplatin, and irinotecan in metastatic pancreatic adenocarcinoma: a Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study","volume":"42","author":"De La Fouchardi\u00e8re","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025061401595509200_CIT0021","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.gcb.2009.03.017","article-title":"Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients","volume":"33","author":"Bachet","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"2025061401595509200_CIT0022","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2025061401595509200_CIT0023","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Royal Stat Soc Ser B: Stat Methodol"},{"key":"2025061401595509200_CIT0024","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10985-007-9048-y","article-title":"On the Breslow estimator","volume":"13","author":"Lin","year":"2007","journal-title":"Lifetime Data Anal"},{"key":"2025061401595509200_CIT0025","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J Royal Stat Soc Ser B: Stat Methodol"},{"key":"2025061401595509200_CIT0026","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for Cox\u2019s proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"key":"2025061401595509200_CIT0027","doi-asserted-by":"crossref","DOI":"10.1201\/9780429492259","volume-title":"Flexible Imputation of Missing Data","author":"Buuren","year":"2018","edition":"Second Edition"},{"key":"2025061401595509200_CIT0028","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/sim.7654","article-title":"Bootstrap inference when using multiple imputation","volume":"37","author":"Schomaker","year":"2018","journal-title":"Stat Med"},{"key":"2025061401595509200_CIT0029","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1175\/1520-0493(1950)078&lt;0001:vofeit&gt;2.0.co;2","article-title":"Verification of forecasts expressed in terms of probability","volume":"78","author":"Brier","year":"1950","journal-title":"Mon Weather Rev"},{"key":"2025061401595509200_CIT0030","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341x.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"2025061401595509200_CIT0031","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MPA.0000000000001455","article-title":"Liposomal irinotecan + 5-FU\/LV in metastatic pancreatic cancer","volume":"49","author":"Macarulla Mercad\u00e9","year":"2020","journal-title":"Pancreas"},{"key":"2025061401595509200_CIT0032","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.pan.2024.06.004","article-title":"The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer","volume":"24","author":"Levine","year":"2024","journal-title":"Pancreatology"},{"key":"2025061401595509200_CIT0033","doi-asserted-by":"publisher","first-page":"1251258","DOI":"10.3389\/fonc.2023.1251258","article-title":"Third-line treatment options in metastatic pancreatic cancer patients: a real-world study","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"2025061401595509200_CIT0034","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1634\/theoncologist.2016-0447","article-title":"Patterns of chemotherapy use in a U.S.-based cohort of patients with metastatic pancreatic cancer","volume":"22","author":"Abrams","year":"2017","journal-title":"Oncologist"},{"key":"2025061401595509200_CIT0035","doi-asserted-by":"publisher","first-page":"15330338211042139","DOI":"10.1177\/15330338211042139","article-title":"Non-pegylated liposomal doxorubicin as palliative chemotherapy in pre-treated advanced pancreatic cancer: a retrospective analysis of twenty-eight patients","volume":"20","author":"Schlick","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"2025061401595509200_CIT0036","doi-asserted-by":"publisher","first-page":"101431","DOI":"10.1016\/j.clinre.2020.03.029","article-title":"Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer: a multicenter prospective AGEO study","volume":"45","author":"Palmieri","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025061401595509200_CIT0037","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01713-w","article-title":"Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study","volume":"126","author":"Zaibet","year":"2022","journal-title":"Br J Cancer"},{"key":"2025061401595509200_CIT0038","doi-asserted-by":"crossref","first-page":"djx037","DOI":"10.1093\/jnci\/djx037","article-title":"Overall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma","volume":"109","author":"Vienot","year":"2017","journal-title":"JNCI, J Natl Cancer Inst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf125\/63488972\/oyaf125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf125\/63488972\/oyaf125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T02:00:05Z","timestamp":1749866405000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf125\/8162465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf125","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf125"}}